The Food and Drug Administration issued further guidance on K-V Pharmaceutical Co.'s (KVA, KVB) Makena drug, recommending health-care providers prescribe the premature-birth drug for clinically-indicated patients rather than use compounded drug formulations.
K-V class A shares surged 23% to 85 cents in recent trading. The stock is down 76% in the past 12 months as of Friday's close.
No comments:
Post a Comment